NEW YORK (GenomeWeb News) – Curetis and Cempra today announced a collaboration for the use of Curetis' Unyvero molecular diagnostic system in Cempra's phase III trial for its oral drug for community-acquired bacterial pneumonia.

Cempra expects to enroll more than 800 patients for the trial, which will compare its solithromyrin oral formulation against a comparator drug in more than 100 clinical sites globally. Samples of sputum will be sent to Curetis for analysis with its Unyvero Solution and Unyvero P50 Pneumonia Application Cartridge.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.